Publication Shows use of Morphologi G3-ID for Component-Specific Particle Characterisation of Pharmaceutical Cream
The application of morphologically directed Raman spectroscopy to charactersing the component-specific particulate properties of the active components in a topical pharmaceutical cream is described in an application note from Malvern Instruments.
Although it is relatively straightforward to determine the particle size distributions of the individual components of a drug formulation before they are formulated as a blend, doing so post-blending is more challenging. Now, the Morphologi G3-ID, which combines automated image analysis with Raman spectroscopy in a single instrument, enables component-specific particle size and shape distributions to be obtained from a blend. The results of this analysis can provide information about the homogeneity and potency of individual components. Such insight is helpful in improving product understanding and can be applied from a regulatory perspective right through to troubleshooting and optimising manufacturing processes.
‘Component specific particle characterisation of active component(s) in topical cream products’ is freely downloadable from the Malvern website. It details the analysis of a commercially available topical cream containing two active ingredients. These two morphologically similar actives could not be differentiated by image analysis alone, however the combination of image analysis with Raman spectroscopy allowed the unambiguous determination of particle size distribution for each component. To download the application note, click here.
The Morphologi G3-ID provides size, shape and chemical analysis information for particles in the size range 0.5–1000 µm for a variety of sample types, including dry powders, liquids and creams. It operates by scanning a particle dispersion and using advanced optics to capture images of individual particles. The system then automatically selects particles within the dispersion and collects a Raman spectrum from each one, allowing them to be classified and grouped in terms of discrete component populations. Designed for operational ease of use, the fully automated instrument enables particle characterization scientists with even limited spectroscopic experience to gain an in-depth understanding of their particulate samples.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance